Lead Product(s): Eicosapentaenoic Acid
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Vascepa
Highest Development Status: Phase IV Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 07, 2020
Study aims to evaluate effects of icosapent ethyl (VASCEPA®) (IPE) on laboratory-confirmed viral upper respiratory infection (URI) rates, clinical impact and outcomes, especially with SARS-CoV-2 infection in adults with established atherosclerotic cardiovascular disease.